Top Story

'Slurry' Kenalog cost-effective, easy alternative for intraocular steroid delivery

February 22, 2017

MIAMI — A single injection of Kenalog lasts for an average of almost 8.5 months and has average or lower side effects compared with other long-term implantable steroid injection devices, according to a speaker here.

“Over 1,000 papers have demonstrated the benefit of Kenalog without a single case of reported retinal toxicity, despite the warnings on this excellent medication. Sterile inflammation has been reported in both the preservative and preservative-free version of this medication, but this is an off-label use of this medication,” Susan M. Malinowski, MD, FACS, said at Angiogenesis, Exudation, and Degeneration 2017.

L. Jay Katz named chief medical officer of Glaukos

February 22, 2017
L. Jay Katz, MD, FACS, has joined Glaukos as its chief medical officer, according to a company press release. Katz, director of the glaucoma service at Wills Eye…

IND active for wet AMD treatment from Regenxbio

February 22, 2017
An investigational new drug application is now active for a phase 1 trial of the wet age-related macular degeneration treatment RGX-314, according to a press release…

Valeant, EyeGate enter licensing agreement

February 21, 2017
Valeant Pharmaceuticals has entered into a licensing agreement with EyeGate Pharmaceuticals regarding the EyeGate II delivery system and EGP-437 combination product…

BLOG: The goblet cell non-controversy

February 21, 2017
One of the neat things about being on the Rubber Chicken Dinner Circuit of industry-sponsored talks is that you get to hear firsthand what it is that your peers are…
More News Headlines »
Clinical Science

Omega Sign: A Distinct Optical Coherence Tomography Finding in Macular Combined Hamartoma of Retina and Retinal Pigment Epithelium

Ophthalmic Surgery, Lasers and Imaging Retina, February 2017, Volume 48 Issue 2
To report a distinct optical coherence tomography (OCT) appearance of macular combined hamartoma of retina and retinal…
More »

Best of Retina Forum® 2016 - Diabetic Retinopathy: A Revolution in Treatment Options

This activity is supported by educational grants from Carl Zeiss Meditec, Inc. and Regeneron Pharmaceuticals, Inc.

Diabetic retinopathy (DR) is an insidious, progressive disease. Diabetic macular edema (DME), which can occur at any…
More »
Hawaiian Eye/Retina Meeting

Hawaiian Eye/Retina Meeting

Video From OSN Europe
Meeting News

VIDEO: Dealing with refractive error after multifocal IOL implantation

February 15, 2017
More »